Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax

A technology of pleural effusion and composition, applied in the application of drugs, kits, in the field of treatment of pleural effusion or pneumothorax, can solve the problem that the drugs for pleural effusion or pneumothorax are not approved, etc.

Inactive Publication Date: 2010-08-11
ISIS INNOVATION LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Drugs currently commonly used to treat pleural effusions or pneumothorax are not approved for this indication

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax
  • Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax
  • Compositions comprising lipoteichoic acid for use in treating pleural effusion or pneumothorax

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0039] method

[0040] This study is a Phase I / IIa toxicity / non-randomized "proof of concept" efficacy trial. The procedure consisted of intrapleural administration of saline control followed by detection of pleural effusion over 7 days followed by administration of LTA-T to evaluate any side effects of LTA-T administration and acute pleural effusion following intrapleural administration of LTA-T. fluid) and frequency of effectiveness of long-term pleurodesis (see Figure 1)

[0041] The patient was an adult aged ≥18 years requiring symptomatic treatment, with histocytologically confirmed malignant pleural effusion.

[0042] After informed consent, an intrapleural catheter (PleurX, Denver, Colorado) was placed in the chest cavity to completely drain the pleural effusion. During the first 14 days of the study, signs of toxicity (clinical symptoms, blood parameters, physical status) were recorded intermittently on a daily basis (Fig. 1)

[0043] After complete evacuation of th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to lipoteichoic acid T for use in treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoteichoic acid T (LTA-T) in the manufacture of a medicament for treating pleural effusion or pneumothorax. The present invention also relates to a kit comprising a pharmaceutical composition comprising lipoteichoic acid T and instructions indicating that the composition is for use as a pleurodesis agent. In addition, the present invention relates to a method of treating pleural effusion or pneumothorax comprising administration of lipoteichoic acid T to a subject.

Description

technical field [0001] The present invention relates to a lipoic acid T for treating pleural effusion or pneumothorax. The present invention also relates to the use of lipoic acid T in the manufacture of medicaments for treating pleural effusion or pneumothorax. The present invention also relates to a kit, wherein the kit comprises a pharmaceutical composition comprising lipicotinic acid T and instructions for use of said composition as a pleurodesis agent. In addition, the present invention also relates to a method for treating pleural effusion or pneumothorax, wherein the method comprises administering lipoic acid T to the patient. Background technique [0002] More than 500,000 patients in Western countries need the adhesion of the parietal pleural membrane and the visceral pleural membrane to make the lung adhere to the chest wall (pleurodesis) to control the undesired intrathoracic (pleural fixation) caused by some diseases. The space between the lungs and the chest w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/739A61P11/00
CPCA61K31/739A61P11/00A61P43/00
Inventor R·J·O·戴维斯
Owner ISIS INNOVATION LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com